| Scanning Babies for Autism A study found that babies and children with autism reacted to hearing bedtime stories in different areas of their brains when compared with their typically-developing peers. online.wsj.com |
PPD Named Best Contract Research Organization in Asia at 2010 Vaccine Industry Excellence Awards (Business Wire) WILMINGTON, N.C.----PPD, Inc. today announced it has been named Best Contract Research Organization in Asia at the World Vaccine Congress’ inaugural 2010 Vaccine Industry Excellence Asia Awards held in Singapore on June 9. us.rd.yahoo.com |
Quest Diagnostics Declares Quarterly Cash Dividend (PR Newswire) Quest Diagnostics Incorporated , the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share, payable on October 19, 2010, to shareholders of record of Quest Diagnostics common stock on October 4, 2010. us.rd.yahoo.com |
Axial Capital Can't Get Enough of QLT Market Folly submits:Hedge fund Axial Capital Management seems to have an insatiable appetite for shares of QLT Inc (QLTI) at current levels. Eliav Assouline and Marc Andersen's hedge fund firm has made the following acquisitions according to multiple SEC Form 4 filings:August 26th: 50,000 shares @ $5.67August 27th: 50,000 shares @ $5.78August 30th: 7,400 shares @ $5.70August 31st: 60,506 shares @ $5.75September 1st: 5,318 shares @ $5.75Complete Story » seekingalpha.com |
Zalicus: Ridiculously Cheap Jeremy Richards submits:CombinatoRx (formerly CRXX) recently changed its name to Zalicus (ZLCS) - a healthy positioned biopharmaceutical company with new and existing product developments. Zalicus is considerably undervalued. and should easily be trading double its current stock price. Zalicus discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. The company's clinical and preclinical product candidates for pain, inflammation, and other central nervous system disorders include Synavive (CRx-102), a novel dissociated glucocorticoid product candidate, which has completed Phase II clinical trials in subjects with knee osteoarthritis, to treat immuno-inflammatory disorders; Prednisporin (FOV1101), a topical ophthalmic drug candidate containing low doses of the glucocorticoid prednisolone acetate and the immunosuppressant cyclosporine A; N-type and T-type calcium channel blockers for the treatment of chronic pain; and CRx-601, a formulation of carbidopa and levodopa for the treatment of Parkinsons disease. It is also developing CRx-401 for Type 2 diabetes; CRx-191 and CRx-197 for psoriasis. It has a research collaboration and license agreement with the Novartis (NVS) Institutes of Biomedical Research; a collaboration agreement with PGxHealth, LLC for the development of ATL313, an adenosine A2A receptor agonist compound owned by PGxHealth; collaboration agreement with Mallinckrodt Inc., Fovea Pharmaceuticals SA, and National Institutes of Allergy and Infectious Diseases; and a cooperative research and development agreement with the United States Army Medical Research Institute for Infectious Diseases.Complete Story » seekingalpha.com |